Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward, California 94545
VIA EDGAR
April 23, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attn: | Mary Beth Breslin |
| Re: | Arcus Biosciences, Inc. |
Registration Statement on FormS-3 |
Filed April 2, 2019 |
FileNo. 333-230676 |
Ladies and Gentlemen:
The undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement onForm S-3 (the “Filing”) to become effective at 4:00 p.m., Eastern Time, on April 25, 2019, or as soon thereafter as is practicable.
Once the Filing has been declared effective, please orally confirm that event with Kenneth L. Guernsey of Cooley LLP, counsel to Arcus Biosciences, Inc., at (415)693-2091, or in his absence, Brett D. White at (650)843-5191.
Sincerely,
/s/ Rekha Hemrajani
Rekha Hemrajani
Chief Financial Officer
| cc: | Carolyn Tang,Arcus Biosciences, Inc. |
Kenneth L. Guernsey,CooleyLLP |
Brett D. White,CooleyLLP |
